Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares
James G. Krueger, Mrinal K. Sarkar, Mark G. Lebwohl, Akimichi Morita, Kenneth Gordon, Rachael Bogle, Christopher Cole, Anthony Coon, Richard G. Langley, Richard B. Warren, Arash Mostaghimi, Bruce Strober, A. David Burden, Min Zheng, Aaron R. Mangold, Milan J. Anadkat, Jonathan N. Barker, Joseph F. Merola, Lam C. Tsoi, Ming Tang, Kolja Becker, Denis Delic, Christian Thoma, Johann E. Gudjonsson
James G. Krueger, Mrinal K. Sarkar, Mark G. Lebwohl, Akimichi Morita, Kenneth Gordon, Rachael Bogle, Christopher Cole, Anthony Coon, Richard G. Langley, Richard B. Warren, Arash Mostaghimi, Bruce Strober, A. David Burden, Min Zheng, Aaron R. Mangold, Milan J. Anadkat, Jonathan N. Barker, Joseph F. Merola, Lam C. Tsoi, Ming Tang, Kolja Becker, Denis Delic, Christian Thoma, Johann E. Gudjonsson
View: Text | PDF
Research Letter Dermatology Inflammation

Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares

Abstract

Authors

James G. Krueger, Mrinal K. Sarkar, Mark G. Lebwohl, Akimichi Morita, Kenneth Gordon, Rachael Bogle, Christopher Cole, Anthony Coon, Richard G. Langley, Richard B. Warren, Arash Mostaghimi, Bruce Strober, A. David Burden, Min Zheng, Aaron R. Mangold, Milan J. Anadkat, Jonathan N. Barker, Joseph F. Merola, Lam C. Tsoi, Ming Tang, Kolja Becker, Denis Delic, Christian Thoma, Johann E. Gudjonsson

×

Figure 1

Changes in proinflammatory gene expression during the study period.

Options: View larger image (or click on image) Download as PowerPoint
Changes in proinflammatory gene expression during the study period. Alte...
Alternative biopsies are indicated by asterisks. The graph shows the gene expression of proinflammatory mediators in all 18 patients who participated in the biomarker study at all time points, including flare and postflare treatment and at the end of the study (week 48). Patients who had a complete series of biopsies throughout the studies are shown (Patients 1–7). One patient had more than 1 biopsy (Patient 6). DEFB4A, defensin β 4A; EoT, end of trial; LD, loading dose; NCF, neutrophil cytosolic factor; q12w, every 12 weeks; q4w, every 4 weeks; TNF, tumor necrosis factor.